UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Trims Stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) by 13.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 41,399 shares of the company’s stock after selling 6,253 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.08% of 4D Molecular Therapeutics worth $448,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. nVerses Capital LLC bought a new stake in 4D Molecular Therapeutics in the third quarter worth about $40,000. Values First Advisors Inc. bought a new position in shares of 4D Molecular Therapeutics during the third quarter valued at approximately $57,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of 4D Molecular Therapeutics by 64.6% in the third quarter. China Universal Asset Management Co. Ltd. now owns 9,995 shares of the company’s stock worth $108,000 after buying an additional 3,922 shares during the period. Proficio Capital Partners LLC purchased a new stake in shares of 4D Molecular Therapeutics in the third quarter worth approximately $108,000. Finally, Quest Partners LLC lifted its stake in shares of 4D Molecular Therapeutics by 17,409.1% during the 2nd quarter. Quest Partners LLC now owns 5,778 shares of the company’s stock worth $121,000 after acquiring an additional 5,745 shares during the last quarter. 99.27% of the stock is owned by hedge funds and other institutional investors.

4D Molecular Therapeutics Stock Performance

NASDAQ FDMT opened at $6.31 on Friday. The company has a market cap of $291.70 million, a PE ratio of -2.21 and a beta of 2.74. 4D Molecular Therapeutics, Inc. has a 52-week low of $5.58 and a 52-week high of $36.25. The firm’s 50 day moving average price is $7.79 and its 200-day moving average price is $13.98.

Wall Street Analysts Forecast Growth

Several brokerages have commented on FDMT. Cantor Fitzgerald downgraded 4D Molecular Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, September 23rd. HC Wainwright reaffirmed a “buy” rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a research note on Thursday, November 14th. Chardan Capital reissued a “buy” rating and issued a $39.00 price objective on shares of 4D Molecular Therapeutics in a research report on Thursday, November 14th. Royal Bank of Canada reduced their target price on shares of 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating on the stock in a research report on Thursday, November 14th. Finally, Leerink Partners reaffirmed an “outperform” rating and set a $36.00 price target (down previously from $40.00) on shares of 4D Molecular Therapeutics in a research note on Thursday, September 19th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, 4D Molecular Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $42.56.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.